USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 - Patent 3224263

(19)

(11)

EP 3 224 263 A1

(12)

(43)	Date of publication:
	04.10.2017 Bulletin 2017/40

(21)	Application number: 15863990.6

(22)	Date of filing: 24.11.2015

(51)

International Patent Classification (IPC):

C07F 5/02^(2006.01)

(86)	International application number:
	PCT/US2015/062347

(87)	International publication number:
	WO 2016/085943 (02.06.2016 Gazette 2016/22)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	MA MD

(30)

Priority:

25.11.2014 US 201462084276 P
02.03.2015 US 201562126749 P

(71)	Applicant: Bioxcel Corporation
	Branford, CT 06405 (US)

(72)	Inventors:
	RASTELLI, Luca Branford, Connecticut 06405 (US) NANDABALAN, Krishnan Branford, Connecticut 06405 (US) SHARMA, Sameer Branford, Connecticut 06405 (US)

(74)	Representative: Cooley (UK) LLP
	Dashwood 69 Old Broad Street London EC2M 1QS London EC2M 1QS (GB)

(54)	USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2